PPARA and metabolic dysfunction-associated steatotic liver disease: Concerning PPAR agonists, there are three different molecules in Phase II trials in NAFLD/NASH patients, such as Saroglitazar, which is a PPAR α/γ agonist (NCT03061721), Lanifibranor, a PPARα/γ/δ agonist (NCT03008070), and Seladelpar, a PPAR δ agonist (NCT03551522).